NYSE:EBS Emergent Biosolutions (EBS) Stock Price, News & Analysis $6.76 +0.40 (+6.35%) Closing price 09/16/2026 03:59 PM EasternExtended Trading$6.74 -0.02 (-0.28%) As of 09/16/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Emergent Biosolutions Stock (NYSE:EBS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Emergent Biosolutions alerts:Sign Up Key Stats Today's Range$6.39▼$6.8050-Day Range$4.44▼$8.1652-Week Range$4.36▼$14.06Volume1.61 million shsAverage Volume1.15 million shsMarket Capitalization$346.79 millionP/E RatioN/ADividend YieldN/APrice Target$10.00Consensus RatingHold Company Overview Emergent BioSolutions Inc. is a life sciences company focused on developing, manufacturing and supplying medical countermeasures and other products intended to address public health threats. Its activities include vaccines, therapeutics and treatments for infectious diseases, overdoses and other emergency health situations, as well as contract development and manufacturing services for pharmaceutical and biotechnology companies. The company’s portfolio has included BioThrax, an anthrax vaccine, and ACAM2000, a smallpox vaccine supplied primarily for preparedness programs. Emergent also manufactures and commercializes NARCAN naloxone nasal spray, which is used to rapidly reverse the effects of an opioid overdose. Its products and services support government preparedness initiatives, healthcare providers, pharmacies and commercial customers. Founded in 1998, Emergent BioSolutions serves customers in the United States and international markets. The company has historically worked closely with U.S. government agencies, including through public-health preparedness contracts, while also serving private-sector pharmaceutical and biotechnology customers through its manufacturing operations.AI Generated. May Contain Errors. Read More Emergent Biosolutions Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks87th Percentile Overall ScoreEBS MarketRank™: Emergent Biosolutions scored higher than 87% of companies evaluated by MarketBeat, and ranked 56th out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.9 / 5Analyst RatingHold Consensus RatingEmergent Biosolutions has received a consensus rating of Hold. The company's average rating score is 2.17, and is based on no strong buy ratings, 3 buy ratings, 1 hold rating, and 2 sell ratings.Upside PotentialEmergent Biosolutions has a consensus price target of $10.00, representing about 47.8% upside from its current price of $6.76.Amount of Analyst CoverageEmergent Biosolutions has only been the subject of 4 research reports in the past 90 days.Read more about Emergent Biosolutions' stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth469.23% Earnings GrowthEarnings for Emergent Biosolutions are expected to grow by 469.23% in the coming year, from $0.13 to $0.74 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Emergent Biosolutions is -1.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Emergent Biosolutions is -1.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEmergent Biosolutions has a P/B Ratio of 0.68. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Emergent Biosolutions' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted22.50% of the float of Emergent Biosolutions has been sold short.Short Interest Ratio / Days to CoverEmergent Biosolutions has a short interest ratio ("days to cover") of 9.15.Change versus previous monthShort interest in Emergent Biosolutions has recently decreased by 6.86%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEmergent Biosolutions does not currently pay a dividend.Dividend GrowthEmergent Biosolutions does not have a long track record of dividend growth. News and Social Media3.4 / 5News Sentiment0.37 News SentimentEmergent Biosolutions has a news sentiment score of 0.37. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.78 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Emergent Biosolutions this week, compared to 3 articles on an average week.Search Interest4 people have searched for EBS on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows2 people have added Emergent Biosolutions to their MarketBeat watchlist in the last 30 days. Company Ownership1.6 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Emergent Biosolutions insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $25,200.00 in company stock.Percentage Held by Insiders6.00% of the stock of Emergent Biosolutions is held by insiders.Percentage Held by Institutions78.40% of the stock of Emergent Biosolutions is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Emergent Biosolutions' insider trading history. Receive EBS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Emergent Biosolutions and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. EBS Stock News HeadlinesINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Emergent BioSolutions Inc. - EBSSeptember 15 at 5:11 PM | globenewswire.comEmergent: The MCM Engine Runs, But Naloxone Is Breaking DownSeptember 15 at 8:57 AM | seekingalpha.comTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result. | Porter & Company (Ad)Media Advisory: Emergent to Host Ribbon Cutting Ceremony at Canton Manufacturing FacilitySeptember 15 at 7:45 AM | globenewswire.comEmergent Biosolutions Highlights Global Public Health CountermeasuresSeptember 14 at 4:50 PM | tipranks.comHC Wainwright Reaffirms "Buy" Rating for Emergent Biosolutions (NYSE:EBS)September 11, 2026 | americanbankingnews.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Emergent BioSolutions Inc. - EBSSeptember 8, 2026 | globenewswire.comEmergent BioSolutions - Tough 2026 Outlook Warrant Rating DowngradeSeptember 6, 2026 | seekingalpha.comSee More Headlines EBS Stock Analysis - Frequently Asked Questions How have EBS shares performed this year? Emergent Biosolutions' stock was trading at $12.35 at the start of the year. Since then, EBS shares have decreased by 45.2% and is now trading at $6.7640. How were Emergent Biosolutions' earnings last quarter? Emergent Biosolutions Inc. (NYSE:EBS) issued its quarterly earnings data on Wednesday, August, 5th. The biopharmaceutical company reported $0.60 EPS for the quarter, beating analysts' consensus estimates of ($0.09) by $0.69. The biopharmaceutical company earned $234.30 million during the quarter, compared to the consensus estimate of $177.50 million. Emergent Biosolutions had a positive trailing twelve-month return on equity of 16.35% and a negative net margin of 22.95%. Read the conference call transcript. Is Emergent Biosolutions doing a stock buyback? Emergent Biosolutions' board approved a stock repurchase plan on Monday, March 31st 2025, which permits the company to buy back $50,000,000 in outstanding shares, according to EventVestor. This means that the company could reacquire up to 19% of its shares through open market purchases. Shares repurchase plans are usually an indication that the company's board of directors believes its shares are undervalued. Who are Emergent Biosolutions' major shareholders? Emergent Biosolutions' top institutional investors include BlackRock Inc. (9.14%), Ancora Advisors LLC (2.08%), Ancora Advisors LLC (2.08%) and Palisade Capital Management LP (1.00%). Insiders that own company stock include Paul Anthony Williams, Coleen Glessner, Donald W Degolyer, Neal Franklin Fowler, Sujata Tyagi Dayal, Ronald Richard, Keith Katkin and Kathryn C Zoon. View institutional ownership trends. How do I buy shares of Emergent Biosolutions? Shares of EBS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Emergent Biosolutions own? Based on aggregate information from My MarketBeat watchlists, some other companies that Emergent Biosolutions investors own include NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Advanced Micro Devices (AMD), Netflix (NFLX), Alibaba Group (BABA) and Moderna (MRNA). Company Calendar Last Earnings8/05/2026Today9/17/2026Next Earnings (Estimated)11/04/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (2m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 EBS's financial health is in the Yellow zone, according to TradeSmith. EBS has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNYSE SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNYSE:EBS CIK1367644 Webwww.emergentbiosolutions.com Phone(240) 631-3200Fax301-795-1899Employees900Year FoundedN/APrice Target and Rating Average Price Target for Emergent Biosolutions$10.00 High Price Target$10.00 Low Price Target$10.00 Potential Upside/Downside+47.8%Consensus RatingHold Rating Score (0-4)2.17 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($3.55) Trailing P/E RatioN/A Forward P/E Ratio52.03 P/E GrowthN/ANet Income$52.60 million Net Margins-22.95% Pretax Margin-18.96% Return on Equity16.35% Return on Assets6.17% Debt Debt-to-Equity Ratio1.70 Current Ratio5.42 Quick Ratio2.95 Sales & Book Value Annual Sales$742.90 million Price / Sales0.47 Cash Flow$3.89 per share Price / Cash Flow1.74 Book Value$9.95 per share Price / Book0.68Miscellaneous Outstanding Shares51,270,000Free Float48,197,000Market Cap$346.79 million OptionableOptionable Beta2.34 Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NYSE:EBS) was last updated on 9/17/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredYour withdrawal order could cost you in taxesIf you have $2M or more saved, the 4% rule points to roughly $92,000 a year - but it's a single-variable answe...SmartAsset | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Emergent Biosolutions Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Emergent Biosolutions With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
